RAS‐targeted cancer therapy: Advances in drugging specific mutations

Rat sarcoma (RAS), as a frequently mutated oncogene, has been studied as an attractive target for treating RAS‐driven cancers for over four decades. However, it is until the recent success of kirsten‐RAS (KRAS)(G12C) inhibitor that RAS gets rid of the title “undruggable”. It is worth noting that the...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Cen, Ye, Danyang, Yang, Hongliu, Chen, Xu, Su, Zhijun, Li, Xia, Ding, Mei, Liu, Yonggang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225044/
https://www.ncbi.nlm.nih.gov/pubmed/37250144
http://dx.doi.org/10.1002/mco2.285

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225044/
https://www.ncbi.nlm.nih.gov/pubmed/37250144
http://dx.doi.org/10.1002/mco2.285

Ejemplares similares